SCHEMBL3834273

SCHEMBL3834273

CC(C)(C)[Si](OC[C@H](O)CCN)(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HRH1 P35367 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP2D6 P10635 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.32
SMYD2 Q9NRG4 2/20 0.32
RIPK1 Q13546 1/20 0.32
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31
ADRB3 P13945 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TSHR P16473 1/20 0.31
AOC3 Q16853 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7155286 0.92 CYP2D6 (0.37) SLC6A2SLC6A4SLC6A3CYP2D6SMN1; SMN2
SCHEMBL15209484 0.88 ALOX15 (0.44) SLC6A2SLC6A4SLC6A3ALOX15CYP2D6
SCHEMBL15209482 0.88 ALOX15 (0.44) SLC6A2SLC6A4SLC6A3ALOX15CYP2D6
SCHEMBL24312400 0.88 CYP2D6 (0.38) SLC6A2SLC6A4SLC6A3CYP2D6SMN1; SMN2
SCHEMBL30335638 0.87 CYP2D6 (0.34) CYP2D6SMN1; SMN2CYP3A4HTTKMT2A
SCHEMBL21873649 0.84 CYP1A2 (0.42) CYP2D6SMN1; SMN2CYP3A4HTTKMT2A
SCHEMBL218117 0.84 CYP1A2 (0.42) CYP2D6SMN1; SMN2CYP3A4HTTKMT2A
SCHEMBL2531862 0.84 CYP1A2 (0.42) CYP2D6SMN1; SMN2CYP3A4HTTKMT2A
SCHEMBL28885789 0.84 TRPA1 (0.36) SLC6A2SLC6A4SLC6A3CYP2D6SMN1; SMN2
SCHEMBL28885790 0.84 TRPA1 (0.36) SLC6A2SLC6A4SLC6A3CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 US disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 US disclosed
EP-2103619-A1 IMIDAZOTHIAZOLE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 SLC6A2 4884/4885SLC6A4 4784/4885SLC6A3 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.